Zhijun Pharmaceutical To Bring Korean Gastric Drug Into China
This article was originally published in PharmAsia News
Executive Summary
Yuhan Corp., the first pharmaceutical company to list in Korea, recently granted Shenzhen Zhijun Pharmaceutical exclusive rights to make and sell its patented gastritis drug Revanex. The licensing agreement marks the strengthening collaboration between China and Korea in conducting R&D. The world's only potassium-competitive acid blocker and new-generation reversible proton pump inhibitor, Revanex has applied for patents in Europe, the U.S., Japan, Korea, China and India. Yuhan was the first Korean drug firm to receive Korea's GMP and GLP authentication and the U.S. cGMP authentication. (Click here for more - Chinese Language)